FY2025 · ended Dec 31, 2025 · Revenue $64,000, -99.8% YoY · Filed Mar 31, 2026
Connect Biopharma Holdings Limited (CNTB) files with the SEC under industry code 2834, Pharmaceutical Preparations. In fiscal 2025, which ended Dec 31, 2025, it reported revenue of $64,000 and a net loss of $55.5 million. Free cash flow was -$51.6 million. As of Jun 30, 2026 it held $31.5 million in cash and investments and $596,000 in total debt.
Revenue (TTM)
$2.95M
Net income (TTM)
$-68.99M
Operating cash flow (TTM)
$-60.58M
Free cash flow (TTM)
$-60.63M
EPS (TTM)
$-1.19
Dividend per share
None
Shares outstanding
56.52M
+2.1% vs prior year
Net cash
$30.89M
as of Jun 30, 2026
Operating margin
-2384.5%
FY 2026
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- CNTB (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- Cayman Islands
- Headquarters
- San Diego, CA
- SEC filer status
- , Emerging growth company
- SEC CIK
- 1835268
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Key figures
Fiscal-year totals from the annual reports. Balance sheet lines are as of each year end.
| Line | FY 2025 Dec 31, 2025 |
FY 2024 Dec 31, 2024 |
|---|---|---|
| Revenue | $64,000 | $26.0M |
| Operating income | -$58.1M | -$22.5M |
| Net income | -$55.5M | -$15.6M |
| Diluted EPS | -$1.00 | -$0.28 |
| Operating cash flow | -$51.2M | -$23.6M |
| Free cash flow | -$51.6M | -$24.4M |
| Total assets | $56.1M | $101.3M |
| Total liabilities | $14.1M | $9.1M |
| Stockholders' equity | $42.0M | $92.2M |
| Cash and investments | $44.3M | $93.7M |
| Total debt | $690,000 | $178,000 |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 8-K |
Current report
Regulation FD disclosure, Other events
|
Sep 30, 2026 | Sep 30, 2026 |
| 8-K |
Current report
Regulation FD disclosure, Other events
|
Sep 15, 2026 | Sep 15, 2026 |
| 10-Q | Quarterly report | Aug 12, 2026 | Jun 30, 2026 |
| 8-K |
Current report
Results of operations
|
Aug 12, 2026 | Aug 12, 2026 |
| 10-Q | Quarterly report | May 12, 2026 | Mar 31, 2026 |
| 8-K |
Current report
Results of operations
|
May 12, 2026 | May 12, 2026 |
All 196 Connect Biopharma Holdings Limited SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.